Drug Pricing
Commentary
Read latest about problems with PBMs
Pharmacy benefit manager reform must remain a priority for Congress
Congress has returned to Capitol Hill from summer recess. Lawmakers in both chambers have a full slate of policy priorities to attend to — not least among them funding the government and averting a shutdown before the Sept. 30 deadline. Several healthcare items will also remain near the top of ...
Commentary
Government Regulation Threatens Life-Saving Innovation
Drug Companies Are Delivering a “Golden Age of Medicine.” Let’s Protect It.
New vaccines for scourges like malaria and respiratory syncytial virus, or RSV. New cancer drugs that can cut death rates by half or even cause complete remission. The discovery of a biomarker that could identify people who would benefit from investigational drugs for Parkinson’s Disease. Breakthrough treatments that curb obesity ...
Commentary
Learn how price controls threaten access to drugs
Despite Democrats’ Celebratory Mood, It’s A Sad Day For American Patients.
President Joe Biden celebrated a milestone today—but American patients have no reason to cheer. The White House announced the first 10 prescription drugs that, starting in 2026, will be subject to price controls authorized by the Inflation Reduction Act . . . It’s laudable that lawmakers want to reduce out-of-pocket ...
Commentary
Read latest on government price controls
Medicaid Drug Price Transparency Rule Is More Sinister Than It Seems
The Biden administration claims to support price transparency in healthcare. The Centers for Medicare and Medicaid Services has formally warned hundreds of hospitals to comply with federal rules requiring them to post their prices publicly. And the agency just rolled out a new rule designed to “advance prescription drug transparency ...
Commentary
Read the latest about PBMs
It’s Time To End the PBM Shakedown
Who says bipartisanship is dead? In the House and Senate, members of both parties are advancing legislation to check the power of pharmacy benefit managers (PBMs), the self-dealing middlemen in the drug supply chain that inflate Americans’ spending on prescriptions by billions of dollars a year. By shining a light ...
Blog
Read more about broken 340B program
340B Advocates Strike Back
There are many reasons why government programs fail to deliver on their intentions, regardless of how well meaning they may be. The rhetoric from too many 340B recipients exemplifies a primary obstacle: Reforms that are necessary to correct a program’s glaring flaws or its fundamental unsustainability are demagogued and labeled ...
Commentary
PBM Industry Shadowy, Congress Shines Much Needed Light
The last few months have seen a flurry of activity on Capitol Hill regarding prescription drug reform, with a particular focus on pharmacy benefit managers, or PBMs. The U.S. Senate Finance Committee is set to markup a bipartisan PBM reform bill within the next few days. The House Energy and Commerce ...
Commentary
Imposing Price Controls Is Never The Answer
The Senate Health, Education, Labor, and Pensions (HELP) Committee is currently reauthorizing the Pandemic and All-Hazards Preparedness Act (PAHPA), which is supposed to help us prepare for the next public health emergency. Never missing an opportunity to impose price controls on anything and everything, Senator Bernie Sanders (I-VT) wants to ...
Commentary
Democrats want to take medicinal price controls further
Senate Democrats Take One More Step Toward Socialized Medicine
It’s been less than a year since Democrats enacted the Inflation Reduction Act, which gives Medicare the power to set the prices of certain medicines. Those price controls have yet to go into effect. But Democrats already want more. They’ve introduced new legislation that would amp up those price controls ...
Commentary
Read the latest on drug price controls
Dems’ Drug Price Controls Would Mean Fewer Drugs And Fewer Jobs
Hundreds of lifesaving therapies will never be invented, and as many as 1.1 million jobs will be lost if Senate Democrats successfully expand their prescription drug price-fixing program, according to a major new study. The study, conducted by the research group Vital Transformation, modeled the effects of the SMART Prices Act. Sponsored ...
Read latest about problems with PBMs
Pharmacy benefit manager reform must remain a priority for Congress
Congress has returned to Capitol Hill from summer recess. Lawmakers in both chambers have a full slate of policy priorities to attend to — not least among them funding the government and averting a shutdown before the Sept. 30 deadline. Several healthcare items will also remain near the top of ...
Government Regulation Threatens Life-Saving Innovation
Drug Companies Are Delivering a “Golden Age of Medicine.” Let’s Protect It.
New vaccines for scourges like malaria and respiratory syncytial virus, or RSV. New cancer drugs that can cut death rates by half or even cause complete remission. The discovery of a biomarker that could identify people who would benefit from investigational drugs for Parkinson’s Disease. Breakthrough treatments that curb obesity ...
Learn how price controls threaten access to drugs
Despite Democrats’ Celebratory Mood, It’s A Sad Day For American Patients.
President Joe Biden celebrated a milestone today—but American patients have no reason to cheer. The White House announced the first 10 prescription drugs that, starting in 2026, will be subject to price controls authorized by the Inflation Reduction Act . . . It’s laudable that lawmakers want to reduce out-of-pocket ...
Read latest on government price controls
Medicaid Drug Price Transparency Rule Is More Sinister Than It Seems
The Biden administration claims to support price transparency in healthcare. The Centers for Medicare and Medicaid Services has formally warned hundreds of hospitals to comply with federal rules requiring them to post their prices publicly. And the agency just rolled out a new rule designed to “advance prescription drug transparency ...
Read the latest about PBMs
It’s Time To End the PBM Shakedown
Who says bipartisanship is dead? In the House and Senate, members of both parties are advancing legislation to check the power of pharmacy benefit managers (PBMs), the self-dealing middlemen in the drug supply chain that inflate Americans’ spending on prescriptions by billions of dollars a year. By shining a light ...
Read more about broken 340B program
340B Advocates Strike Back
There are many reasons why government programs fail to deliver on their intentions, regardless of how well meaning they may be. The rhetoric from too many 340B recipients exemplifies a primary obstacle: Reforms that are necessary to correct a program’s glaring flaws or its fundamental unsustainability are demagogued and labeled ...
PBM Industry Shadowy, Congress Shines Much Needed Light
The last few months have seen a flurry of activity on Capitol Hill regarding prescription drug reform, with a particular focus on pharmacy benefit managers, or PBMs. The U.S. Senate Finance Committee is set to markup a bipartisan PBM reform bill within the next few days. The House Energy and Commerce ...
Imposing Price Controls Is Never The Answer
The Senate Health, Education, Labor, and Pensions (HELP) Committee is currently reauthorizing the Pandemic and All-Hazards Preparedness Act (PAHPA), which is supposed to help us prepare for the next public health emergency. Never missing an opportunity to impose price controls on anything and everything, Senator Bernie Sanders (I-VT) wants to ...
Democrats want to take medicinal price controls further
Senate Democrats Take One More Step Toward Socialized Medicine
It’s been less than a year since Democrats enacted the Inflation Reduction Act, which gives Medicare the power to set the prices of certain medicines. Those price controls have yet to go into effect. But Democrats already want more. They’ve introduced new legislation that would amp up those price controls ...
Read the latest on drug price controls
Dems’ Drug Price Controls Would Mean Fewer Drugs And Fewer Jobs
Hundreds of lifesaving therapies will never be invented, and as many as 1.1 million jobs will be lost if Senate Democrats successfully expand their prescription drug price-fixing program, according to a major new study. The study, conducted by the research group Vital Transformation, modeled the effects of the SMART Prices Act. Sponsored ...
